多替拉韦每日两次联合每日一次利福喷丁与异烟肼1个月方案用于结核预防
A5372是一项多中心药代动力学研究,在已接受含多替拉韦抗逆转录病毒治疗且HIV RNA<50拷贝/mL的HIV感染者中,评估1个月每日利福喷丁/异烟肼(1HP)期间将多替拉韦增至50 mg每日两次的药代动力学、病毒学与安全性。结果显示第28天多替拉韦谷浓度高于第0天,几何均值比为1.05(90%CI 0.93-1.2,P=0.43),无严重不良事件,31/32例在1HP结束时HIV RNA<50拷贝/mL。
要点
- 1HP期间多替拉韦50 mg每日两次的谷浓度高于未用1HP时标准剂量每日一次。
- 第28天与第0天多替拉韦谷浓度几何均值比为1.05(90%CI 0.93-1.2,P=0.43)。
- 32例中31例在1HP结束时HIV RNA<50拷贝/mL,无严重不良事件报告。
核心结论
- 1HP治疗期间多替拉韦50 mg每日两次的谷浓度高于未用1HP时标准剂量每日一次。
- 这些药代动力学、病毒学与安全性数据支持将多替拉韦每日两次与1HP联合用于结核预防。
研究设计与样本
- A5372是一项多中心药代动力学研究,纳入已接受含多替拉韦抗逆转录病毒治疗且HIV RNA<50拷贝/mL的≥18岁HIV感染者。
- 参与者接受每日利福喷丁/异烟肼(600 mg/300 mg)共28天作为1HP方案的一部分,期间多替拉韦增至50 mg每日两次,并在第0天(1HP前)和1HP治疗最后一天进行密集药代动力学采样。
- 32例参与者纳入药代动力学分析(41%女性;66% Black/African;中位[Q1,Q3]年龄42[34,49]岁)。
主要发现
- 31例在1HP给药结束时HIV RNA<50拷贝/mL;1例在第28天HIV RNA为160拷贝/mL,第42天重复检测时HIV RNA<50拷贝/mL。
- 多替拉韦谷浓度中位(Q1,Q3)第0天为1751 ng/mL(1195,2542),第28天为1987 ng/mL(1331,2278)。
- 第28天与第0天多替拉韦谷浓度几何均值比为1.05(90%CI 0.93-1.2;P=0.43)。
- 未报告严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for tuberculosis prevention in people with human immunodeficiency virus (HIV). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. AIDS Clinical Trials Group A5372 evaluated the effect of 1HP on the pharmacokinetics of twice-daily dolutegravir. METHODS: A5372 was a multicenter, pharmacokinetic study in people with HIV (≥18 years) already on dolutegravir-containing antiretroviral therapy with HIV RNA <50 copies/mL. Participants received daily rifapentine/isoniazid (600 mg/300 mg) for 28 days as part of 1HP. Dolutegravir was increased to 50 mg twice daily during 1HP, and intensive pharmacokinetic sampling was performed on day 0 (before 1HP) and on the final day of 1HP treatment. RESULTS: Thirty-two participants (41% female; 66% Black/African; median [Q1, Q3] age, 42 [34, 49] years) were included in the pharmacokinetic analysis; 31 had HIV RNA <50 copies/mL at the end of 1HP dosing. One participant had an HIV RNA of 160 copies/mL at day 28, with HIV RNA <50 copies/mL upon repeat testing on day 42. The median (Q1, Q3) dolutegravir trough concentration was 1751 ng/mL (1195, 2542) on day 0 versus 1987 ng/mL (1331, 2278) on day 28 (day 28:day 0 geometric mean ratio, 1.05 [90% confidence interval, .93-1.2]; P = .43). No serious adverse events were reported. CONCLUSIONS: Dolutegravir trough concentrations with 50 mg twice-daily dosing during 1HP treatment were greater than those with standard-dose dolutegravir once daily without 1HP. These pharmacokinetic, virologic, and safety data provide support for twice-daily dolutegravir use in combination with 1HP for tuberculosis prevention. CLINICAL TRIALS REGISTRATION: NCT04272242.
引用
- Podany AT, Cramer Y, Imperial M, et al. Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2024. PMID: 38568956. doi:10.1093/cid/ciae183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。